Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Clinical trial NCT05618028 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT05618028

Sponsor

AbbVie

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2023-04-04

Primary completion

2029-07-01

Enrollment

78

View on ClinicalTrials.gov